Funder
Japanese Government Ministry of Education, Culture, Sports, Science, and Technology
Publisher
Springer Science and Business Media LLC
Reference90 articles.
1. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281
2. Wu K, Yang Q, Liu Y, Wu A, Yang Z (2014) Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. World J Surg Oncol 12:95. https://doi.org/10.1186/1477-7819-12-95
3. Martin M, Romero A, Cheang MCU, Lopez Garcıa-Asenjo JU, Garcıa-Saenz JA, Oliva B, Roman JM, He X, Casado A, de la Torre J, Furio J, Puente J, Caldes T, Vidart JA, Lopez-Tarruella S, Diaz-Rubio E, Perou CM (2011) Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat 128:127–136
4. Wahba HA, El-Hadaad HA (2015) Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med 12(2):106–116
5. Székely B, Silber AL, Pusztai L (2017) New therapeutic strategies for triple-negative breast cancer. Oncology 31(2):130–137
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献